Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT05006794
Title	Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies
Recruitment	Recruiting
Gender
Phase	Phase I
Variant Requirements	Yes
Sponsors	Gilead Sciences
Indications	lung small cell carcinoma endometrial cancer lung non-small cell carcinoma gastric adenocarcinoma gastrointestinal stromal tumor Kaposi's sarcoma thyroid gland follicular carcinoma malignant mesothelioma gastroesophageal junction adenocarcinoma head and neck squamous cell carcinoma triple-receptor negative breast cancer transitional cell carcinoma esophageal cancer clear cell renal cell carcinoma ovary epithelial cancer colorectal cancer cervical cancer hepatocellular carcinoma breast cancer prostate cancer
Therapies	GS-9716 + Sacituzumab govitecan-hziy GS-9716 Docetaxel + GS-9716
Age Groups:	senior \| adult
Covered Countries	USA

Facility	Status	City	State	Zip	Country	Details
START Midwest	RECRUITING	Grand Rapids	Michigan	49546	United States	Details
START Mountain Region	RECRUITING	Grand Rapids	Michigan	49546	United States	Details
Oregon Health Oregon Health & Sciences University-Knight Cancer Institute	RECRUITING	Portland	Oregon	97239	United States	Details
Sarah Cannon Research Institute	RECRUITING	Nashville	Tennessee	37203	United States	Details
START San Antonio	RECRUITING	San Antonio	Texas	78229	United States	Details

*Shaded cells indicate that there was no data available from clincialtrials.gov for the field